Solid lipid nanoparticles with surface antibody for targeting the brain and inhibiting lymphatic phagocytosis

Journal of the Taiwan Institute of Chemical Engineers

Volumn 45, Issue 4, 2014, Pages 1154-1163

  Kuo, Yung Chih ^a   Shih Huang, Chun Yuan ^a  

^a NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

Author keywords

Monoclonal antibody; Phagocytosis; Saquinavir; Solid lipid nanoparticle; Targeting

Indexed keywords

BLOOD; EMULSIONS; ENDOTHELIAL CELLS; ENZYME INHIBITION; GRAFTING (CHEMICAL); MONOCLONAL ANTIBODIES; NANOPARTICLES;

HUMAN BRAIN-MICROVASCULAR ENDOTHELIAL CELLS; IMMUNOCHEMICAL STAINING; MONOCLONAL ANTIBODIES (MAB); PHAGOCYTOSIS; SAQUINAVIR; SOLID LIPID NANOPARTICLE (SLN); SOLID LIPID NANOPARTICLES; TARGETING;

ANTIGEN-ANTIBODY REACTIONS;

EID: 84903374712     PISSN: 18761070     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtice.2014.01.017     Document Type: Article

References (80)

1. Levy J.A. HIV pathogenesis: 25 years of progress and persistent challenges. AIDS 2009, 23:147-160.
2. Ganser-Pornillos B.K., Yeager M., Sundquist W.I. The structural biology of HIV assembly. Curr Opin Struc Biol 2008, 18:203-217.
3. de Silva T.I., Cotten M., Rowland-Jones S.L. HIV-2: the forgotten AIDS virus. Trends Microbiol 2008, 16:588-595.
4. Noble S., Faulds D. Saquinavir a review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996, 52:93-112.
5. Fitzsimmons M.E., Collins J.M. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4-Potential contribution to high first-pass metabolism. Drug Metab Dispos 1997, 25:256-266.
6. Bauer B., Hartz A.M.S., Fricker G., Miller D.S. Modulation of p-glycoprotein transport function at the blood-brain barrier. Exp Biol Med 2005, 230:118-127.
7. Bachmeier C.J., Spitzenberger T.J., Elmquist W.F., Miller D.W. Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm Res 2005, 22:1259-1268.
8. Kuo Y.C., Su F.L. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. Int J Pharm 2007, 340:143-152.
9. Souto E.B., Muller R.H. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Handb Exp Pharmacol 2010, 197:115-141.
10. Chung C.Y., Yang J.T., Kuo Y.C. Polybutylcyanoacrylate nanoparticles for delivering hormone response element-conjugated neurotrophin-3 to the brain of intracerebral hemorrhagic rats. Biomaterials 2013, 34:9717-9727.
11. Kocbek P., Baumgartner S., Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm 2006, 312:179-186.
12. Kuo Y.C., Chung C.Y. Solid lipid nanoparticles comprising internal Compritol 888 ATO, tripalmitin and cacao butter for encapsulating and releasing stavudine, delavirdine and saquinavir. Colloids Surf B 2011, 88:682-690.
13. Bocca C., Caputo O., Cavalli R., Gabriel L., Miglietta A., Gasco M.R. Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles. Int J Pharm 1998, 175:185-193.
14. Muller R.H., Mehnert W., Lucks J.S., Schwarz C., Zur Muhlen A., Weyhers H., et al. Solid lipid nanoparticles (SLN)-an alternative colloidal drug carrier system for controlled drug delivery. Eur J Pharm 1995, 41:62-69.
15. Troster S.D., Muler U., Kreuter J. Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants. Int J Pharm 1990, 61:85-100.
16. Jones A.R., Shusta E.V. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res 2007, 24:1759-1771.
17. Kuo Y.C., Wang C.C. Cationic solid lipid nanoparticles with primary and quaternary amines for release of saquinavir and biocompatibility with endothelia. Colloids Surf B 2013, 101:101-105.
18. Kuo Y.C., Chen I.C. Evaluation of surface charge density and surface potential by electrophoretic mobility for solid lipid nanoparticles and human brain-microvascular endothelial cells. J Phys Chem B 2007, 111:11228-11236.
19. Kuo Y.C., Lu C.H. Regulation of endocytosis into human brain-microvascular endothelial cells by inhibition of efflux proteins. Colloids Surf B 2011, 87:139-145.
20. Kuo Y.C., Lu C.H. Effect of human astrocytes on the characteristics of human brain-microvascular endothelial cells in the blood-brain barrier. Colloids Surf B 2011, 86:225-231.
21. Kuo Y.C., Chen H.H. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier. Int J Pharm 2006, 327:160-169.
22. Shi L.J., Li Z., Yu L., Jia H., Zheng L.Q. Effects of surfactants and lipids on the preparation of solid lipid nanoparticles using double emulsion method. J Disper Sci Technol 2011, 32:254-259.
23. Jenning V., Thunemann A.F., Gohla S.H. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm 2000, 199:167-177.
24. Souto E.B., Anselmi C., Centini M., Muller R.H. Preparation and characterization of n-dodecyl-ferulate-loaded solid lipid nanoparticles. Int J Pharm 2005, 295:261-268.
25. Muller R.H., Mader K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000, 50:161-177.
26. Kastantin M., Ananthanarayanan B., Karmali P., Ruoslahti E., Tirrell M. Effect of the lipid chain melting transition on the stability of DSPE-PEG(2000) micelles. Langmuir 2009, 25:7279-7286.
27. Teeranachaideekul V., Muller R.H., Junyaprasertv V.B. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)-effects of formulation parameters on physicochemical stability. Int J Pharm 2007, 340:198-206.
28. Pu N.W., Wang C.A., Liu Y.M., Sung Y., Wang D.S., Ger M.D. Dispersion of graphene in aqueous solutions with different types of surfactants and the production of graphene films by spray or drop coating. J Taiwan Inst Chem Eng 2012, 43:140-146.
29. Davoodi-Nasab P., Abolghasemi H., Safdari J., Raji-Asadabadi M. Study on the simultaneous effect of silica nanoparticles and cetyl trimethyl ammonium bromide on drop size in mixer-settler extractor. J Taiwan Inst Chem Eng 2013, [in press]. 10.1016/j.jtice.2013.02.006.
30. Romero-Cano M.S., Martin-Rodriguez A., Chauveteau G., De Las Nieves F.J. Electrokinetic characterization of polystyrene-non-ionic surfactant complexes. Colloids Surf A 1998, 140:347-356.
31. Kuo Y.C., Wang C.C. Surface molecular composition and electrical property of cationic solid lipid nanoparticles with assembled lipid layer mediated by noncovalent interactions. J Phys Chem C 2012, 116:16999-17007.
32. Kuo Y.C., Wang C.C. Electrophoresis of human brain microvascular endothelial cells with uptake of cationic solid lipid nanoparticles: effect of surfactant composition. Colloids Surf B 2010, 76:286-291.
33. Lim S.J., Kim C.K. Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. Int J Pharm 2002, 243:135-146.
34. Olbrich C., Muller R.H. Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int J Pharm 1999, 180:31-39.
35. Vivek K., Reddy H., Murthy R.S.R. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles. AAPS PharmSciTech 2007, 8:E1-E9.
36. Kim B.D., Na K., Choi H.K. Preparation and characterization of solid lipid nanoparticles (SLN) made of cacao butter and curdlan. Eur J Pharm Sci 2005, 24:199-205.
37. 1-receptor antagonist. Chem Pharm Bull 2002, 50:87-91.
38. Hafez I.M., Ansell S., Cullis P.R. Tunable pH-sensitive liposomes composed of mixtures of cationic and anionic lipids. Biophys J 2000, 79:1438-1446.
39. Bottari E., D'Archivio A.A., Festa M.R., Galantini L., Giglio E. Structure and composition of sodium taurocholate micellar aggregates. Langmuir 1999, 15:2996-2998.
40. Spector A.A. Fatty acid binding to plasma albumin. J Lipid Res 1975, 16:165-179.
41. Brink J., Jonsson A.S., Jonsson B., Lindau J. Influence of pH on the adsorptive fouling of ultrafiltration membranes by fatty acid. J Membr Sci 2000, 164:187-194.
42. Rawat M.K., Jain A., Singh S. In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats. J Pharm Sci 2011, 6:2406-2417.
43. Kuo Y.C., Shih-Huang C.Y. Solid lipid nanoparticles carrying chemotherapeutic drug across the blood-brain barrier through insulin receptor-mediated pathway. J Drug Target 2013, 21:730-738.
44. Liu Y.S., Wen C.F., Yang Y.M. Development of ethosome-like catanionic vesicles for dermal drug delivery. J Taiwan Inst Chem Eng 2012, 43:830-838.
45. Kinoshita M., Nakatsuji Y., Suzuki S., Hayakawa T., Kakehi K. Quality assurance of monoclonal antibody pharmaceuticals based on their charge variants using microchip isoelectric focusing method. J Chromatogr A 2013, 1309:76-83.
46. Maruyama K., Takizawa T., Yuda T., Kennel S.J., Huang L., Iwatsuru M. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim Biophys Acta 1995, 1234:74-80.
47. Nobs L., Buchegger F., Gurny R., Allemann E. Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci 2004, 93:1980-1992.
48. Chan J.M., Zhang L., Yuet K.P., Liao G., Rhee J.W., Langer R., et al. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials 2009, 30:1627-1634.
49. Kuo Y.C., Chung J.F. Physicochemical properties of nevirapine-loaded solid lipid nanoparticles and nanostructured lipid carriers. Colloids Surf B 2011, 83:299-306.
50. Deng L., Zhang Y., Ma L., Jing X., Ke X., Lian J., et al. Comparison of anti-EGFR-Fab' conjugated immunoliposomes modified with two different conjugation linkers for siRNA delivery in SMMC-7721 cells. Int J Nanomed 2013, 8:3271-3283.
51. Kuo Y.C., Wang L.J. Transferrin-grafted catanionic solid lipid nanoparticles for targeting delivery of saquinavir to the brain. J Taiwan Inst Chem Eng 2013, [in press]. 10.1016/j.jtice.2013.09.024.
52. Glynn S.L., Yazdanian M. In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J Pharm Sci 1998, 87:306-310.
53. Prigent S.A., Stanley K.K., Siddle K. Identification of epitopes on the human insulin receptor reacting with rabbit polyclonal antisera and mouse monoclonal antibodies. J Biol Chem 1990, 265:9970-9977.
54. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001, 47:65-81.
55. Weisgraber K.H., Innerarity T.L., Harder K.J. The receptor-binding domain of human apolipoprotein E monoclonal antibody inhibition of binding. J Biol Chem 1983, 258:12348-12354.
56. Troster S.D., Kreuter J., Muller U. Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants. Int J Pharm 1990, 61:81-100.
57. Borchard G., Audus K.L., Shi F., Kreuter J. Uptake of surfactant-coated poly(methyl methacrylate) nanoparticles by bovine brain microvessel endothelial cell monolayers. Int J Pharm 1994, 110:29-35.
58. Kreuter J., Alyautdin R.N., Kharkevich D.A., Gothier D., Petrov V. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly (butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm 1995, 41:44-48.
59. Kreuter J., Alyautdin R.N., Kharkevich D.A., Petrov V.E., Langer K., Berthold A. Delivery of lopermide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res 1997, 14:325-328.
60. Kreuter J., Alyautdin R.N., Kharkevich D.A., Tezikov E.B., Ramge P., Begley D.J. Significant entry of tubocurarine into brain of rats by adsorption to polysorbate 80-coated polybutyl-cyanoacrylate nanoparticles: an in situ brain perfusion study. J Microencapsul 1998, 15:67-74.
61. van Bree J.B.M.M., de Boer A.G., Danhof M., Ginsel L.A., Breimer D.D. Characterization of an "in vitro" blood-brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. J Pharmacol Exp Ther 1998, 247:1233-1239.
62. Fontana G., Licciardi M., Mansueto S., Schillaci D., Giammona G. Amoxicillin-loaded polyethylcyano-acrylate nanoparticles: influence of PEG coating on the particle size, drug release rate and phagocytic uptake. Biomaterials 2001, 22:2857-2865.
63. Scholer N., Hahn H., Muller R.H., Liesenfeid O. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int J Pharm 2002, 231:167-176.
64. Klose D., Siepmann F., Elkharraz K., Krenzlin S., Siepmann J. How porosity and size affect the drug release mechanisms from PLGA-based microparticles. Int J Pharm 2006, 314:198-206.
65. Kuo Y.C., Kuo C.Y. Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers. Int J Pharm 2008, 351:271-281.
66. Kuo Y.C., Liang C.T. Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. Biomaterials 2011, 32:3340-3350.
67. Rejman J., Oberle V., Zuhorn I.S., Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 2004, 377:159-169.
68. Kuo Y.C., Chen H.H. Effect of electromagnetic field on endocytosis of cationic solid lipid nanoparticles by human brain-microvascular endothelial cells. J Drug Target 2010, 18:447-456.
69. Kuo Y.C., Ko H.F. 83-14 monoclonal antibody-grafted solid lipid nanoparticles for targeting delivery of saquinavir into the brain. Biomaterials 2013, 34:4818-4830.
70. Storm G., Belliot S.O., Daemen T., Lasic D.D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 1995, 17:31-48.
71. Kumari S., Mg S., Mayor S. Endocytosis unplugged: multiple ways to enter the cell. Cell Res 2010, 20:256-275.
72. Herd H., Daum N., Jones A.T., Huwer H., Ghandehari H., Lehr C.M. Nanoparticle geometry and surface orientation influence mode of cellular uptake. ACS Nano 2013, 7:1961-1973.
73. He C., Hu Y., Yin L., Tang C., Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010, 31:3657-3666.
74. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008, 5:505-515.
75. Clift M.J.D., Rutishauser B.R., Brown D.M., Duffin R., Donaldson K., Proudfoot L., et al. The impact of different nanoparticle surface chemistry and size on uptake and toxicity in a murine macrophage cell line. Toxicol Appl Pharmacol 2008, 232:418-427.
76. Gratton S.E.A., Napier M.E., Ropp P.A., Tian S., DeSimone J.M. Microfabricated particles for engineered drug therapies: elucidation into the mechanisms of cellular internalization of print particles. Pharm Res 2008, 25:2845-2852.
77. Gratton S.E.A., Ropp P.A., Pohlhaus P.D., Luft J.C., Madden V.J., Napier M.E., et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A 2008, 105:11613-11618.
78. Kuo Y.C., Lin P.I., Wang C.C. Targeting nevirapine delivery across human brain microvesscular endothelial cells using transferrin-grafted poly(lactide-co-glycolide) nanoparticles. Nanomedicine 2011, 6:1011-1026.
79. Wu D., Yang J., Pardridge W.M. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J Clin Invest 1997, 100:1804-1812.
80. Fenart L., Casanova A., Dehock B., Duhem C., Slupek S., Cecchelli R., et al. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood brain barrier. J Parmacol Exp Ther 1999, 291:1017-1022.